The book Photodynamic Therapy of Ocular Diseases provides a very detailed account of the development of photodynamic therapy in ophthalmology. It features an emphasis on preclinical studies (10 chapters of 23 total), early clinical trials of several agents, and a review of the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin In Photodynamic Therapy (VIP) trials.
No printed book can possibly hope to be current in such a rapidly changing field. It seems unfair to list the important changes in the field that have occurred since this book was released to the printer; however, clinicians must be forewarned that this book does not mention the phase III results of the photodynamic agent tin ethyl etiopurpurin trials for age-related macular degeneration, nor the phase III results of Macugen (Eyetech Pharmaceuticals, New York City, NY) for comparison purposes with verteporfin photodynamic therapy. Visudyne (QLT Inc, Vancouver, Canada) was not yet approved by the Centers for Medicare and Medicaid Services for occult choroidal neovascularization when this was written, and it omits the recommendation by Genentech (San Francisco, Calif) that Lucentis intravitreal injection should occur noncontemporaneously from Visudyne therapy because of concerns about inactivation of the antivascular endothelial growth factor drug. No doubt, other important new information will become available in the field even before this review is published. The lack of current information is an unavoidable disadvantage for general ophthalmologists and most retinologists who read the book.
Photodynamic Therapy of Ocular Diseases. Arch Ophthalmol. 2005;123(1):131. doi:10.1001/archopht.123.1.131